In the present study, we speculated that the biomarkers SLC2A1, TLE1, FAM83A, HMGA2, FBXO44, and MTRNR2L12, which are resistant to AMG510 treatment for LUAD due to tumor heterogeneity, significantly correlate with CD4 memory-activated T cells, M1 macrophages, Tregs, etc. Significant correlations affect the development of tumor therapy resistance, but the specific mechanisms need to be further demonstrated. This evidence concerns the gene FBXO44 and neoplasm.